ORAL DOSAGE OF ANTI-AIDS AGENTS

这种资源功能的目标是开发和生产 药学上可接受的剂型或有前途的新药剂， 抗艾滋病活动。一些药物由药物选择委员会在 NIH将被指定开发和生产口服产品。 最初，预计I期和II期的批量较小 审判然而，III/IV期试验的批量扩大 C组分布情况预计。估计这 一个项目必须准备生产数百万个口服剂量单位 每年.

The objective of this resource function is to develop and produce pharmaceutically acceptable dosage forms or promising new agents with anti-AIDS activity. Some agents selected by a Drug Selection Committee at NIH will be assigned for development and manufacture asoral products. Initially, the batch sizes are expected to be small for Phase I and II trials. However, escalation to large batch sizes for Phase III/IV trials and Group C distribution is anticipated. It is estimated that this project must be prepared to produce several million oral dosage units each year.